TM FDA Approves Eisai’s LENVIMA (lenvatinib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer • • - Progressive - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2015-02-24 17:47:41		TM FDA Approves Eisai’s LENVIMA (lenvatinib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer • • Add to Reading List Source URL: www.thyroid.org Download Document from Source Website File Size: 109,79 KB Share Document on Facebook